• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

9.760 +0.020 (+0.21%)
Official Closing Price Updated: 7:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
January 16, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From Organon & Co.
Via Business Wire
News headline image
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
November 17, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
November 14, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Organon Reports Results for the Third Quarter Ended September 30, 2025
November 10, 2025
From Organon & Co.
Via Business Wire
News headline image
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
November 08, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
November 07, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
November 06, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
October 28, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation
October 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox is Investigating Organon &amp; Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation
October 27, 2025
Via TheNewswire.com
News headline image
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
October 27, 2025
From Organon
Via Business Wire
News headline image
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
September 02, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon Reports Results for the Second Quarter Ended June 30, 2025
August 05, 2025
From Organon & Co.
Via Business Wire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
July 22, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
July 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Organon &amp; Co. Sued for Securities Law Violations - Investors Should Contact Levi &amp; Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
July 22, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit
July 22, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
July 22, 2025
From Organon & Co.
Via Business Wire
News headline image
Deadline Soon: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
July 21, 2025
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
DEADLINE TOMORROW: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action by July 22, 2025
July 21, 2025
From Berger Montague
Via GlobeNewswire
News headline image
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - OGN
July 21, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Organon &amp; Co. Sued for Securities Law Violations - Investors Should Contact Levi &amp; Korsinsky for More Information - OGN
July 21, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ORGANON & CO. (NYSE: OGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Organon & Co. Investors of Upcoming Deadline
July 21, 2025
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
July 20, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit
July 19, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co. - OGN
July 18, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
July 18, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Organon &amp; Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
July 18, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN
July 18, 2025
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap